Xiogenix began as a family-owned business in 2001, entering the market as a steel rule die maker, providing solutions to the printing, packaging and leather making industries.
Previous ownership saw an opportunity to take an old technology and reimagine biologic cutting dies and clean room compatible presses. In late 2017, Milwaukee-based Breakthru Family of Companies acquired Xiogenix. Breakthru is a strategic long-term advisor, investor and partner led company by co-founders Jerry Jendusa and James Harasha, formerly of EMTEQ Aerospace. Under BreakthU, Xiogenix has expanded the tissue banking market to include a multitude of products for processing soft, hard and birth tissues. In 2022, Xiogenix entered into the cell & gene therapy market with innovations in fill & finish, cell suspension and cryopreservation. Xiognix holds an advantage over large pharmaceutical-type automation houses. Our vast experience in designing through the constraints of aseptic processing and creating solutions appropriately suited for the market sector sets us apart. With over 40% of its staff as engineers, Xiogenix has extensive industry and technical knowledge. With customization and niche market offerings, Xiogenix understands that any products designed, developed and validated within the market must be supported extensively.